Department of Vascular Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Expert Opin Pharmacother. 2010 Apr;11(5):739-53. doi: 10.1517/14656561003592169.
Atherosclerosis, the condition underlying cardiovascular disease (CVD), often begins in childhood. A disturbance in lipoprotein metabolism is one of the major modifiable risk factors for the development of atherosclerosis and ensuing CVD. Therefore, strategies to prevent CVD should be implemented at an early age, especially in populations at high risk.
We discuss the current treatment options for a number of primary and secondary dyslipidaemias. A literature search was done using PubMed, and references from 1973 to 2009 are cited.
The reader will gain a comprehensive review on pharmacological and non-pharmacological treatment options for primary and secondary dyslipidaemia in childhood.
Dyslipidaemia may require early diagnosis and management, especially when it is familial with elevated cholesterol levels from birth onwards. If target goals for low-density lipoprotein reduction cannot be reached with lifestyle modification, drug therapy can be considered.
动脉粥样硬化，心血管疾病（CVD）的发病基础，通常始于儿童期。脂蛋白代谢紊乱是动脉粥样硬化和随后的 CVD 发展的主要可改变危险因素之一。因此，预防 CVD 的策略应在早期实施，尤其是在高危人群中。
我们讨论了多种原发性和继发性血脂异常的当前治疗选择。使用 PubMed 进行文献检索，并引用了 1973 年至 2009 年的参考文献。
读者将全面了解儿童原发性和继发性血脂异常的药物和非药物治疗选择。
血脂异常可能需要早期诊断和治疗，特别是当它是家族性的，出生后胆固醇水平就升高时。如果通过生活方式改变不能达到降低低密度脂蛋白的目标，可考虑药物治疗。
